Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) is evaluating acquisition of a majority stake in US-based Ardelyx, Inc. (NasdaqGM:ARDX), with the deal likely to be valued at $2.2 billion-$2.5 billion, two people aware of the development told Mint. The proposed transaction would be funded through a INR 50,000 million equity raise via a qualified institutional placement (QIP) and internal cash accruals, the people said. If concluded, the deal would significantly accelerate Zydus's push into global innovative medicine, an avenue that is attracting growing interest from Indian drugmakers.
Ardelyx is a biopharmaceutical firm working on first-in-class small-molecule drugs and commercializing novel medicines with a focus mainly on gastrointestinal (GI) and cardio-renal diseases, where there are significant unmet patient needs. The company's market capitalization as of 20 January on Nasdaq is $1.7 billion. It reported a revenue of $378 million in 2025, up 18%.
Emailed queries sent to Zydus Lifesciences and Ardelyx remained unanswered until press time.
